{"doi":"10.1007/s00259-025-07275-2","title":"Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice","abstract":"<jats:title>Abstract</jats:title>\n          <jats:sec>\n            <jats:title>Purpose</jats:title>\n            <jats:p>Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer’s disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and FDG-PET in determining progression to AD among patients with aMCI.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Methods</jats:title>\n            <jats:p>This study recruited 145 patients with aMCI from October 2013 to March 2021. The patients were classified into four groups based on whether Amyloid-PET (A) and FDG-PET (N) were positive (+) or negative (-). The patients were then clinically followed to establish progression to dementia due to AD.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Results</jats:title>\n            <jats:p>Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased. The conversion from aMCI to AD had a global mean time of 39.95 months. However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54–81] vs. 32.59 months [CI 20.56–40.74] months). Taking both tests together, the time to conversion was faster in A+/N + versus A+/N- patients (27.79 [CI 20.40–33.21] vs. 37.38 [CI 20.73–48.26] months).</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions</jats:title>\n            <jats:p>Among patients with aMCI, those with a positive Amyloid-PET and an AD pattern on FDG-PET progressed to dementia significantly earlier versus those with a positive Amyloid-PET only. Using both biomarkers during the initial diagnosis enhances the prediction of short-term conversion.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number</jats:title>\n            <jats:p>Not applicable. It is not a clinical trial.</jats:p>\n          </jats:sec>","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2025,"id":630092,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1569763,"name":"Elena Prieto","orcid":null,"position":1,"is_corresponding":false},{"id":1632199,"name":"Edgar Fernando Guillén","orcid":null,"position":2,"is_corresponding":false},{"id":1632200,"name":"Adolfo Jimenez","orcid":null,"position":3,"is_corresponding":false},{"id":67344,"name":"Genoveva Montoya","orcid":null,"position":4,"is_corresponding":false},{"id":1632201,"name":"Rafael Villino","orcid":null,"position":5,"is_corresponding":false},{"id":1260180,"name":"Mario Riverol","orcid":"0000-0002-4383-9127","position":6,"is_corresponding":false},{"id":1475529,"name":"Javier Arbizu","orcid":"0000-0002-8370-5510","position":7,"is_corresponding":false},{"id":1632198,"name":"Beatriz Echeveste","orcid":"0000-0003-1469-0826","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice","abstract":"<jats:title>Abstract</jats:title>\n          <jats:sec>\n            <jats:title>Purpose</jats:title>\n            <jats:p>Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer’s disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and FDG-PET in determining progression to AD among patients with aMCI.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Methods</jats:title>\n            <jats:p>This study recruited 145 patients with aMCI from October 2013 to March 2021. The patients were classified into four groups based on whether Amyloid-PET (A) and FDG-PET (N) were positive (+) or negative (-). The patients were then clinically followed to establish progression to dementia due to AD.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Results</jats:title>\n            <jats:p>Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased. The conversion from aMCI to AD had a global mean time of 39.95 months. However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54–81] vs. 32.59 months [CI 20.56–40.74] months). Taking both tests together, the time to conversion was faster in A+/N + versus A+/N- patients (27.79 [CI 20.40–33.21] vs. 37.38 [CI 20.73–48.26] months).</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions</jats:title>\n            <jats:p>Among patients with aMCI, those with a positive Amyloid-PET and an AD pattern on FDG-PET progressed to dementia significantly earlier versus those with a positive Amyloid-PET only. Using both biomarkers during the initial diagnosis enhances the prediction of short-term conversion.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number</jats:title>\n            <jats:p>Not applicable. It is not a clinical trial.</jats:p>\n          </jats:sec>","is_dataset_classified":null,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40257609","pmcid":"PMC12316835","openalex_id":"https://openalex.org/W4409652221","authors":[],"funders":[{"funder_name":"Universidad de Navarra","grant_id":"","title":null}],"total_grants":1,"fwci":5.5918,"citation_percentile":0.96324875,"influential_citations":0,"citation_trend":[{"year":2025,"count":4},{"year":2026,"count":3}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s00259-025-07275-2.pdf","host_type":"journal"},{"url":"https://link.springer.com/content/pdf/10.1007/s00259-025-07275-2.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s00259-025-07275-2/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s00259-025-07275-2","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40257609","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12316835","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12316835/pdf/259_2025_Article_7275.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12316835","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12316835?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Dementia and Cognitive Impairment Research","Alzheimer's disease research and treatments","Intracerebral and Subarachnoid Hemorrhage Research"],"mesh_terms":["Aged","Aged, 80 and over","Alzheimer Disease","Amyloid","Female","Humans","Male","Middle Aged","Disease Progression","Fluorodeoxyglucose F18","Positron-Emission Tomography","Cognitive Dysfunction"],"keywords":["Medicine","Neurodegeneration","Amyloid (mycology)","Dementia","Internal medicine","Predictive value","Pittsburgh compound B","Positron emission tomography","Disease","Alzheimer's disease","Standardized uptake value","Oncology","Gastroenterology","Pathology","Nuclear medicine","Fdg-pet","Alzheimer’s Disease (Ad)","Amnestic Mild Cognitive Impairment (Amci)","Amyloid-pet","Short-term Conversion"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T20:27:54.848761Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}